Arovella Therapeutics partners with Cell Therapies to develop its ALA-101 manufacturing process for cancer clinical trials
Cell Therapies Pty Ltd is partnering with Arovella Therapeutics (ASX: ALA) to develop the manufacturing process for Arovella’s ALA-101 product candidate to treat cancer patients in upcoming clinical trials. The ALA-101 product incorporates Arovella’s invariant natural killer T (iNKT) cell therapy platform from Imperial College London in combination with a Chimeric Antigen Receptor (CAR) targeting CD19. ALA-101 is being developed as an allogeneic cell therapy, providing an “off-the-shelf” solution for CD19-expressing cancers. Arovella’s CEO and MD, Dr Michael Baker, commented: “We are delighted to partner with Cell Therapies to manufacture ALA-101. Cell Therapies have a proven track record manufacturing cell-based therapeutics for patients and we believe they are the ideal partner to get our therapy into the hands of people suffering from CD19-expressing blood cancers. We are looking forward to a strong partnership.”
